Dimethyl Sulfoxide
Apexbio Technology LLC CAL-101 (Idelalisib, GS-1101) 870281-82-6 10mM (in 1mL DMSO)
CAL-101 (Idelalisib GS-1101 CAS 870281-82-6) is a selective inhibitor targeting the p110 isoform of phosphatidylinositol 3-kinase (PI3K) an enzyme involved in signaling pathways critical for proliferation and survival of malignant B cells By inhibiting PI3K p110 CAL-101 reduces PI3K-mediated phosphorylation of Akt and other downstream factors leading to enhanced PARP cleavage and caspase activation ultimately inducing apoptosis in malignant B cells CAL-101 has been demonstrated to counteract survival signals initiated by molecules such as CD40 ligand (CD40L) TNF- and fibronectin This agent is valuable in investigating B-cell malignancies
Apexbio Technology LLC A66 1166227-08-2 10mM (in 1mL DMSO)
A66 (CAS 1166227-08-2) is a selective inhibitor of the p110 catalytic subunit of class I phosphatidylinositol-4 5-bisphosphate 3-kinase (PI3K) with an IC50 of 32 nM This compound specifically decreases phosphorylation of Akt/PKB and downstream S6K at Thr389 in various cell models including PIK3CA-mutant H1047R cell lines C2C12 myoblasts and 3T3-L1 adipocytes In animal studies A66 reduces tumor growth in xenograft models and improves insulin sensitivity under chronic metabolic stress highlighting its utility in research on PI3K signaling in cancer and metabolic disease
Apexbio Technology LLC Sephin1 13098-73-2 10mM (in 1mL DMSO)
Sephin1 (CAS 13098-73-2) is a selective inhibitor of PPP1R15A a regulatory subunit of protein phosphatase 1 involved in the regulation of stress-induced eIF2 dephosphorylation Under endoplasmic reticulum (ER) stress phosphorylated eIF2 attenuates protein synthesis preventing accumulation of misfolded proteins By inhibiting PPP1R15A Sephin1 sustains eIF2 phosphorylation extending translational attenuation during ER stress In cell assays Sephin1 selectively disrupts PPP1R15A-PP1c complexes without affecting PPP1R15B-mediated complexes In mouse models harboring misfolded protein mutations (e g MPZ or SOD1) Sephin1 administration mitigates molecular cellular and functional deficits thus relevant for proteostasis-related disease studies
Apexbio Technology LLC Cyclopamine 4449-51-8 10mM (in 1mL DMSO)
Cyclopamine (CAS 4449-51-8) is a naturally occurring steroidal alkaloid that selectively inhibits the Hedgehog (Hh) signaling pathway a conserved cascade involved in cellular proliferation and differentiation In human breast cancer cell lines (MCF-7 and MDA-MB-231) cyclopamine treatment (10 20 M) significantly suppresses proliferation induces cell cycle arrest at G1 phase and reduces invasive capabilities In FXR-bla assays cyclopamine exhibits an EC50 of 10 57 M As an Hh-antagonist it is widely utilized in research examining embryogenesis cancer biology tumor invasiveness and developmental defects
Apexbio Technology LLC Fludarabine(Synonyms: Fludarabine Phosphate, Fludara, Fludarabinum, 2-Fluoro-ara-AMP, 9H-Purin-6-amine), 10mM (in 1mL DMSO), CAS: 21679-14-1.
Fludarabine (CAS 21679-14-1) is a purine analog prodrug that inhibits DNA synthesis Upon cellular uptake it undergoes phosphorylation to its active triphosphate form (F-ara-ATP) disrupting DNA replication through inhibition of critical enzymes such as DNA primase DNA ligase I ribonucleotide reductase and DNA polymerases and In human myeloma RPMI8226 cell assays fludarabine suppressed cell growth reduced Akt phosphorylation and lowered anti-apoptotic proteins XIAP and Survivin In vivo studies demonstrated marked tumor growth inhibition in RPMI8226 xenograft models Fludarabine serves as a tool in oncology research particularly leukemia and multiple myeloma-related studies
Apexbio Technology LLC Reparixin 266359-83-5 10mM (in 1mL DMSO)
Reparixin (CAS 266359-83-5) is a noncompetitive allosteric inhibitor of chemokine receptors CXCR1 and CXCR2 which are seven-transmembrane G-protein coupled receptors involved notably in acute inflammatory responses Reparixin specifically disrupts CXCR1/2-mediated neutrophil recruitment and migration without affecting other receptor pathways In murine ischemia-reperfusion injury models Reparixin administration significantly inhibits neutrophil influx and associated inflammation-related tissue damage Thus Reparixin serves as a valuable research tool for investigating CXCR-dependent inflammatory mechanisms and evaluating therapeutic potentials in conditions such as acute lung injury and spinal cord damage
Apexbio Technology LLC Hyoscyamine(Synonyms: Levsin, Anaspaz, Daturine, Atropine sulfate (isomer), Hyoscyamin, Tropine tropate, (-)-Hyoscyamine), 10mM (in 1mL DMSO), CAS: 101-31-5.
Hyoscyamine (CAS 101-31-5) is a small molecule antagonist targeting acetylcholine receptors (AChR) Acting via inhibition of cholinergic signaling it exhibits a potent inhibitory activity with an IC50 of approximately 7 5 nM By blocking AChRs hyoscyamine modulates neurotransmission pathways involved in autonomic regulation Research applications include studies exploring cholinergic function investigations into parasympathetic nervous system disorders and testing therapeutic strategies involving ACh modulation
Apexbio Technology LLC Tolcapone 134308-13-7 10mM (in 1mL DMSO)
Tolcapone (CAS 134308-13-7) is an orally bioavailable reversible small-molecule inhibitor targeting catechol-O-methyltransferase (COMT) Acting through competitive inhibition tolcapone structurally incorporates a catechol moiety with electron-withdrawing substituents facilitating anionic formation that binds potently to COMT s catalytic site (reported IC50 of approximately 36 nM in rat liver assays) By competitively occupying this active site tolcapone prevents the enzymatic methylation of endogenous catechols such as levodopa thus prolonging levodopa s bioavailability Tolcapone is primarily investigated as adjunctive therapeutic agent in Parkinson s disease research enabling reduced levodopa dosage while enhancing symptomatic control
Apexbio Technology LLC BIRB 796 (Doramapimod) 285983-48-4 10mM (in 1mL DMSO)
BIRB 796 (Doramapimod CAS 285983-48-4) is a potent inhibitor of human p38 mitogen-activated protein kinase (MAPK) which modulates the signaling pathways associated with inflammatory cytokine production It demonstrates significant inhibition of TNF- release (EC50 18 nM) in THP-1 cells In animal models oral administration reduces LPS-induced TNF- synthesis and ameliorates collagen-induced arthritis severity Clinically however trials for Crohn s disease showed no superiority over placebo BIRB 796 serves as a valuable research tool in inflammation and cytokine signaling studies
Apexbio Technology LLC ORY-1001 1431326-61-2 10mM (in 1mL DMSO)
ORY-1001 is a selective inhibitor targeting the lysine-specific histone demethylase KDM1A (also known as LSD1) an FAD-dependent amine oxidase enzyme responsible for the removal of histone methylation marks particularly dimethylation of histone H3 lysine 4 (H3K4me2) By inhibiting KDM1A ORY-1001 promotes accumulation of H3K4me2 at gene targets and induces cellular differentiation in acute myeloid leukemia (AML) cell models In vitro assays demonstrated dose- and time-dependent increases in H3K4me2 and expression of differentiation markers in treated AML cells ORY-1001 exhibited oral bioavailability in animal xenograft models reducing tumor growth at low daily doses This molecule serves as a valuable research tool in epigenetics oncology pharmacology and studies regarding AML differentiation pathways with ongoing evaluation in early-phase clinical trials
Selleck Chemical LLC Trametinib DMSO solvate S4484-25mg
Trametinib DMSO solvate is a highly specific and potent MEK1/2 inhibitor with IC50 of 0 92 nM/1 8 nM in cell-free assay Trametinib activates autophagy and induces apoptosis
Apexbio Technology LLC Pazopanib (GW-786034) 444731-52-6 10mM (in 1mL DMSO)
Pazopanib (GW-786034 CAS 444731-52-6) is a second-generation multitargeted receptor tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptors (VEGFR) platelet-derived growth factor receptors (PDGFR) and c-kit Through blockade of these kinase activities pazopanib suppresses signaling cascades essential for angiogenesis and cellular proliferation Preclinical tumor models indicate that pazopanib alone or combined with chemotherapy demonstrates substantial anti-angiogenic and antitumor efficacy Its distinct inhibitory profile of intracellular VEGFR tyrosine kinases offers valuable applications in oncology research particularly in investigating angiogenesis-driven signaling pathways
Medchemexpress LLC Solid Solvent 10Mm 1Ml Dmso | HY-162288 SOLID +SOLVENT
Solid Solvent 10Mm 1Ml Dmso